Theranostics News and Research

RSS

Breakthrough imaging method enhances precision in prostate cancer treatment

A novel SPECT/CT acquisition method can accurately detect radiopharmaceutical biodistribution in a convenient manner for prostate cancer patients, opening the door for more personalized treatment.

17 Apr 2024

PET/MRI combination reduces unnecessary prostate biopsies, study shows

PET/MRI can improve diagnostic accuracy for prostate cancer patients and help avoid unnecessary biopsies, according to new research published in the April issue of The Journal of Nuclear Medicine.

13 Apr 2024

Non-invasive detection and treatment of ovarian cancer with new radiotheranostic system

A new radiotheranostic system has the ability to detect and treat ovarian cancer noninvasively, according to new research published in the April issue of The Journal of Nuclear Medicine.

4 Apr 2024

Lancet Commission predicts sharp increase in global prostate cancer cases

Cases of prostate cancer are projected to double from 1.4 million per year in 2020 to 2.9 million per year by 2040, with low- and middle-income countries (LMICs) predicted to see the highest increases in cases, according to The Lancet Commission on prostate cancer which will be launched by a presentation at the European Association of Urology Congress.

4 Apr 2024

New method for detecting and treating breast cancer subtypes

The most prevalent disease in women, breast cancer, poses a major risk to the health of women.

2 Apr 2024

New DNA nanomachine targets breast cancer with precision

Breast cancer is the most common malignancy in women, posing a serious threat to the female health. Due to the high inter- and intra-tumoral heterogeneity of breast cancer, clinical treatment and prognosis can vary greatly in patients.

28 Mar 2024

New method developed for triggering and imaging seizures in epilepsy patients

Researchers have developed a new method for triggering and imaging seizures in epilepsy patients, offering physicians the ability to collect real-time data to tailor epilepsy surgery.

11 Mar 2024

New PET radiotracer distinguishes diseased tissues based on fructose metabolism

A new PET radiotracer can differentiate diseased tissues from healthy tissues based on fructose metabolism, according to new research published in the March issue of The Journal of Nuclear Medicine.

8 Mar 2024

Collaborative project gets $20 million to develop new radiopharmaceutical cancer therapies

UT Health Science Center researchers Gabor Tigyi, MD, PhD, Harriet Van Vleet Endowment Professor in Basic Oncology Research, Junming Yue, PhD, associate professor in the Department of Pathology, Sue Chin Lee, PhD, in the Department of Physiology, and David Schwartz, MD, chair of the Department of Radiation Oncology, are part of a scientific leadership group awarded $20 million from the University of Tennessee-Oak Ridge Innovation Institute in partnership with Oak Ridge National Laboratory and the University of Tennessee, Knoxville, to develop new radiopharmaceutical therapies to treat cancer.

21 Feb 2024

Closing the Cancer Care Gap with the Power of Precision Oncology

According to American Cancer Society, Cancer causes about 1 in every 6 deaths globally, more than AIDS, tuberculosis, and malaria combined.

From MGI 5 Feb 2024

New drug kills tumor cells by triggering a deadly calcium storm

Calcium ions are essential for cells, but can be toxic in higher concentrations. A team of researchers has now designed and prepared a combination drug that kills tumor cells by modulating the calcium influx into the cell.

30 Jan 2024

Novel imaging approach accurately identifies sub-types of primary aldosteronism

A novel imaging approach, 68Ga-pentixafor PET/CT, has been shown to accurately identify sub-types of primary aldosteronism (an adrenal gland disorder), outperforming traditional methods for diagnosis.

18 Jan 2024

Promising PET scanner tool developed for rare medullary thyroid cancer

A newly developed PET imaging agent has been found to be effective in identifying medullary thyroid cancer (MTC) in preclinical and clinical studies, according to research published in the January issue of The Journal of Nuclear Medicine.

11 Jan 2024

New guidelines for imaging estrogen receptor in breast cancer patients using FES PET

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the European Association of Nuclear Medicine (EANM) have issued a new procedure standard/practice guideline for estrogen receptor imaging of breast cancer patients using FES PET.

5 Jan 2024

68Ga-FAPI PET imaging superior to existing methods for detecting pancreatic cancer

PET imaging with 68Ga-FAPI can more effectively detect and stage pancreatic cancer as compared with 18F-FDG imaging or contrast-enhanced CT, according to new research published in the December issue of The Journal of Nuclear Medicine.

2 Jan 2024

Novel PET tracer accurately detects common cancer mutation for tailored treatment

A novel PET imaging tracer has been proven to safely and effectively detect a common cancer gene mutation that is an important molecular marker for tumor-targeted therapy.

2 Jan 2024

New radio-theranostics approach shows promise in the fight against pancreatic cancer

Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers worldwide, with a 5-year survival rate of less than 10%. Many PDAC tumors in early stage go undetected because they are not found using conventional imaging methods, including fluorodeoxyglucose positron emission tomography (PET) scans.

15 Oct 2023

Does your gut microbiome play a role in therapeutic outcomes?

The role of the gut microbiome and its metabolites in altering the therapeutic outcomes

12 Oct 2023

New tau PET radiotracer shows promise for early detection of Alzheimer's disease

A new tau PET radiotracer, 18F-SNFT-1, has been found to be more effective than existing tau PET radiotracers in identifying Alzheimer's disease in its earliest stages, according to research published in the September issue of The Journal of Nuclear Medicine.

29 Sep 2023

New imaging agent predicts early metabolic response to HER2-targeted therapy in metastatic breast cancer

A new imaging agent, 68Ga-ABY-025, can predict early metabolic response to human epidermal growth factor receptor 2 (HER2)-targeted treatment in HER2-positive metastatic breast cancer patients, according to new research published in the September issue of The Journal of Nuclear Medicine.

27 Sep 2023